FEP 633
Alternative Names: FEP-633Latest Information Update: 17 Jun 2022
At a glance
- Originator PRISM BioLab
- Class Antineoplastics; Small molecules
- Mechanism of Action Eukaryotic initiation factor 4E inhibitors; Eukaryotic initiation factor-4G inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bladder cancer
Highest Development Phases
- Preclinical Bladder cancer; Urogenital cancer
Most Recent Events
- 17 Jun 2022 Preclinical trials in Urogenital cancer in Japan (unspecified route) before June 2022 (PRISM BioLab pipeline, June 2022)
- 17 Jun 2022 Pharmacodynamics data from preclinical studies in Urethelial cancer released by PRISM-BioLab before June 2022 (PRISM-BioLab pipeline, June 2022)
- 16 Jun 2022 FEP 633 is available for licensing as of 16 Jun 2022. https://prismbiolab.com/